Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.


first to design and bring stereopure and allele-specific medicines to clinic


neurology development
programs by end of 2018


clinical studies
initiated in 2017


nucleic acid modalities being advanced with Wave stereopure chemistry


discovery programs


therapeutic areas under active investigation


Investor Relations

Recent News

Recent News

Recent News and Events

Copyright Nasdaq. Minimum 15 minutes delayed.